ArticleCancer management and research2020

miR-210 is a Serological Biomarker for Predicting Recurrence and Prognosis of Colon Carcinoma Patients with Liver Metastases After Radiofrequency Ablation Treatment.

Yong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.